| Literature DB >> 27099174 |
Sangyeul Han1, Seung-Jun Lee2, Kyung Eun Kim3, Hyo Seon Lee3, Nuri Oh4, Inwon Park5, Eun Ko3, Seung Ja Oh3, Yoon-Sook Lee3, David Kim4, Seungjoo Lee4, Dae Hyun Lee4, Kwang-Hoon Lee3, Su Young Chae3, Jung-Hoon Lee3, Su-Jin Kim3, Hyung-Chan Kim3, Seokkyun Kim3, Sung Hyun Kim3, Chungho Kim6, Yoshikazu Nakaoka7, Yulong He8, Hellmut G Augustin9, Junhao Hu10, Paul H Song3, Yong-In Kim3, Pilhan Kim5, Injune Kim4, Gou Young Koh11.
Abstract
Protection of endothelial integrity has been recognized as a frontline approach to alleviating sepsis progression, yet no effective agent for preserving endothelial integrity is available. Using an unusual anti-angiopoietin 2 (ANG2) antibody, ABTAA (ANG2-binding and TIE2-activating antibody), we show that activation of the endothelial receptor TIE2 protects the vasculature from septic damage and provides survival benefit in three sepsis mouse models. Upon binding to ANG2, ABTAA triggers clustering of ANG2, assembling an ABTAA/ANG2 complex that can subsequently bind and activate TIE2. Compared with a conventional ANG2-blocking antibody, ABTAA was highly effective in augmenting survival from sepsis by strengthening the endothelial glycocalyx, reducing cytokine storms, vascular leakage, and rarefaction, and mitigating organ damage. Together, our data advance the role of TIE2 activation in ameliorating sepsis progression and open a potential therapeutic avenue for sepsis to address the lack of sepsis-specific treatment.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27099174 DOI: 10.1126/scitranslmed.aad9260
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956